United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 150 mg in 1 ml - medroxyprogesterone acetate injectable suspension is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use medroxyprogesterone acetate injectable suspension long-term [ see warnings and precautions ( 5.1) ]. the use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [ see warnings and precautions ( 5.2) ]. - known or suspected malignancy of breast [ see warnings and precautions ( 5.3) ]. - known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients [ see warnings and precautions ( 5.5)

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 10 mg - tablet, uncoated - excipient ingredients: calcium stearate; lactose monohydrate; sucrose; purified talc; liquid paraffin; maize starch - 1.carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2.endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding, in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 10 mg - tablet, uncoated - excipient ingredients: sucrose; purified talc; liquid paraffin; calcium stearate; lactose monohydrate; maize starch - 1.carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2.endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding, in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 5 mg - tablet, uncoated - excipient ingredients: calcium stearate; liquid paraffin; sucrose; lactose monohydrate; indigo carmine; maize starch; purified talc - 1.carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2.endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding, in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 10 mg - tablet, uncoated - excipient ingredients: purified talc; sucrose; lactose monohydrate; maize starch; calcium stearate; liquid paraffin - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; calcium stearate; liquid paraffin; sucrose; purified talc; maize starch - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 5 mg - tablet, uncoated - excipient ingredients: indigo carmine; maize starch; sucrose; purified talc; liquid paraffin; calcium stearate; lactose monohydrate - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; purified talc; calcium stearate; liquid paraffin; maize starch; sunset yellow fcf; sucrose - 1.carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4.abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: isopropyl alcohol; maize starch; purified water; gelatin; sodium starch glycollate; sodium benzoate; magnesium stearate; microcrystalline cellulose; macrogol 400; docusate sodium - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 150 mg/ml - injection, suspension - excipient ingredients: propyl hydroxybenzoate; methyl hydroxybenzoate; water for injections; sodium chloride; macrogol 3350; polysorbate 80 - carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contra- indicated or has been unsuccessful. contraception (ovulation suppression): for long-term prevention of pregnancy in women when administered at 3-month intervals. since loss of bone mineral density (bmd) may occur in pre-menopausal women who use depo-provera long-term (greater than 2 years), women should be assessed, before starting treatment for contraception or endometriosis, regarding the risk of osteoporosis. women under the age of 18 years may be at risk of failing to achieve their predicted peak bone mineral density (see warnings). the 50 mg/1ml vial is not approved for the indication of contraception (ovulation suppression). the injection, depo-provera 1